Personalis (NASDAQ:PSNL) Rating Lowered to Hold at Craig Hallum

Key Points

• Craig Hallum downgraded Personalis from “Buy” to “Hold” and set a $16.25 price target, implying 11.59% downside from the stock’s $18.38 opening price.
• Analyst sentiment is mixed but centers on a consensus “Hold” rating, with an average price target of $14.54; ratings include four Buys, four Holds and two Sells.
• Personalis reported quarterly revenue of $22.36 million, above estimates, but its $0.30-per-share loss exceeded expectations. Insiders have sold 435,032 shares worth roughly $5.6 million over the past 90 days.

Personalis (NASDAQ:PSNL - Get Free Report) was downgraded by stock analysts at Craig Hallum from a "buy" rating to a "hold" rating in a note issued to investors on Monday. They presently have a $16.25 target price on the stock. Craig Hallum's price objective would suggest a potential downside of 11.59% from the stock's current price.

A number of other equities analysts have also recently commented on PSNL. Zacks Research cut Personalis from a "hold" rating to a "strong sell" rating in a report on Tuesday, July 21st. Wall Street Zen lowered Personalis from a "hold" rating to a "sell" rating in a report on Saturday, June 13th. Morgan Stanley upped their price target on Personalis from $9.00 to $13.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 9th. BTIG Research raised their price objective on Personalis from $11.00 to $16.25 and gave the stock a "buy" rating in a research note on Monday, July 20th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Personalis in a research report on Wednesday, July 15th. Four investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $14.54.

Personalis Stock Performance

Shares of NASDAQ PSNL opened at $18.38 on Monday. Personalis has a 12-month low of $4.65 and a 12-month high of $18.89. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -16.86 and a beta of 2.27. The firm has a 50 day moving average of $13.30 and a 200 day moving average of $9.68.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The business had revenue of $22.36 million during the quarter, compared to the consensus estimate of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. Sell-side analysts predict that Personalis will post -1.07 EPS for the current year.

Insiders Place Their Bets

In other Personalis news, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.15, for a total value of $1,315,000.00. Following the completion of the sale, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,103,215.90. This represents a 29.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the firm's stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.18, for a total value of $675,488.18. Following the sale, the chief financial officer directly owned 198,833 shares in the company, valued at approximately $2,620,618.94. This represents a 20.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 435,032 shares of company stock worth $5,599,929. 4.20% of the stock is owned by corporate insiders.

Institutional Trading of Personalis

Several institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd lifted its holdings in Personalis by 76.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company's stock worth $27,000 after purchasing an additional 1,479 shares in the last quarter. Legal & General Group Plc bought a new position in Personalis in the 2nd quarter worth approximately $30,000. International Assets Investment Management LLC bought a new position in Personalis in the 4th quarter worth approximately $31,000. BNP Paribas Financial Markets grew its holdings in Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company's stock valued at $42,000 after buying an additional 5,177 shares in the last quarter. Finally, Focus Partners Wealth purchased a new stake in Personalis during the 1st quarter valued at approximately $47,000. Hedge funds and other institutional investors own 61.91% of the company's stock.

Personalis Company Profile

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source